In recent months, vaccine stocks have been among the most heavily traded companies on the stock market. Over $250 billion is what Moderna and Biontech are currently worth. Biontech’s performance since its IPO in 2019 has been 2,440%.
But this week Biontech had to give up some gains on the stock markets. Concerns about certain rare side effects following vaccinations against COVID-19 weighed heavily on shares of mRNA vaccine makers Moderna and Biontech in U.S. trading Wednesday. Currently, Biontech is trading about 18 percent below its all-time high.
But Biontech may soon be much more than Corona vaccine. With its mRNA technology, the company could achieve a breakthrough in the fight against malaria and even cancer.
For more updates, follow us on Twitter: @JRC_Capital